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CaOBJECTIVES The aim of this study was to compare outcomes of ST-segment elevation myocardial infarction (STEMI)
patients with a history of coronary artery bypass graft surgery (CABG), previous percutaneous coronary intervention
(PCI), or no previous revascularization undergoing primary PCI.
BACKGROUND Limited data exist regarding door-to-balloon times and clinical outcomes of STEMI patients with a
history of CABG or PCI undergoing primary PCI.
METHODS We examined 15,628 STEMI patients who underwent primary PCI at 297 sites in the United States. We used
multivariable logistic regression analyses to compare door-to-balloon time delays >90 min and in-hospital major adverse
cardiovascular or cerebrovascular events (MACCE).
RESULTS Patients with previous CABG were signiﬁcantly older and more likely to have multiple comorbidities
(p < 0.0001). Previous CABG was associated with a lower likelihood of a door-to-balloon time #90 min compared with
patients with no previous revascularization. However, no signiﬁcant differences in door-to-balloon times were noted
between patients with previous PCI and those without previous revascularization. The unadjusted MACCE risk was
signiﬁcantly higher in patients with a history of CABG compared with patients without previous revascularization (odds
ratio: 1.68, 95% conﬁdence interval: 1.23 to 2.31). However, after multivariable risk adjustment, there were no signiﬁcant
differences in MACCE risk between the 2 groups. No signiﬁcant differences in in-hospital outcomes were seen in patients
with a previous PCI and those without previous revascularization.
CONCLUSIONS In a large cohort of STEMI patients undergoing primary PCI, patients with previous CABG were more
likely to have reperfusion delays, yet risk-adjusted, in-hospital outcomes were similar to those without previous revas-
cularization. No signiﬁcant differences in reperfusion timeliness and in-hospital outcomes were seen in patients with a
history of PCI compared with patients without previous revascularization. (J Am Coll Cardiol Intv 2015;8:1954–62)
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AB BR E V I A T I O N S
AND ACRONYM S
CABG = coronary artery bypass
graft surgery
CI = conﬁdence interval
GWTG = Get With the
Guidelines
MACCE = major adverse
cardiovascular or
cerebrovascular event(s)
MI = myocardial infarction
OR = odds ratio
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
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1955P rimary percutaneous coronary intervention(PCI) is currently a Class I indication and thedefault strategy for the management of pa-
tients with ST-segment elevation myocardial infarc-
tion (STEMI) if it can be performed in a timely
manner (1–3). However, current guidelines for the
management of STEMI patients make no reference
to door-to-balloon time goals for patients who have
had a previous surgical or percutaneous coronary
revascularization procedure who may have more
complex coronary anatomy or require additional
diagnostic image acquisition to inform decision mak-
ing (1). There are limited data comparing outcomes
between patients with and without previous coronary
revascularization. Previous reports have indicated
that the prevalence of STEMI after previous coronary
artery bypass graft surgery (CABG) ranges from 2% to
14% (4,5) and, although infrequent, is associated withSEE PAGE 1963worse clinical outcomes (6–9). Early studies per-
formed with ﬁbrinolytic therapy showed poor angio-
graphic success and higher mortality rates in these
patients (10,11). The advent of percutaneous translu-
minal coronary angioplasty did not seem to improve
the outcomes of these patients (5,8,9,12). More recent
studies using intracoronary stenting showed that pa-
tients with previous CABG had signiﬁcantly higher
mortality rates than those without previous revascu-
larization, especially if the infarct-related lesion was
located in a bypass graft (4,13–15). Conversely, a
recent study of acute myocardial infarction (MI) pa-
tients undergoing PCI for a previously stented culprit
lesion had signiﬁcantly lower mortality rates
compared with patients who had a PCI for a de novo
culprit lesion (16). However, there is no contemporary
study that directly compares in a single cohort the
outcomes of primary PCI among STEMI patients
with previous CABG, previous PCI, or no previous
revascularization.
By merging 2 datasets of the National Cardiovas-
cular Data Registry, the CathPCI Registry and the
Acute Coronary Treatment and Intervention Out-
comes Network (ACTION) Registry and Get With
the Guidelines, we were able to assess both inter-
ventional and in-hospital clinical outcomes on theSpeakers Bureau of AstraZeneca and Janssen. Dr. Wang has received researc
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Manuscript received June 1, 2015; revised manuscript received July 21, 2015basis of the patient’s revascularization his-
tory and the culprit lesion treated. We sought
to compare reperfusion timeliness and in-
hospital outcomes after primary PCI among
STEMI patients with a history of CABG, pa-
tients with a history of PCI, and those without
previous revascularization.
METHODS
STUDY POPULATION. The mission of the
National Cardiovascular Data Registry,
developed by the American College of Cardi-
ology Foundation, is to improve the quality of
cardiovascular patient care by measuring
adherence to performance metrics, providing
direct feedback to participating sites together with
knowledge and tools to improve performance (17). The
ACTION (Acute Coronary Treatment and Intervention
Outcomes Network) Registry–GWTG (Get With the
Guidelines) was designed to assess the characteristics,
treatments, and outcomes of consecutive STEMI or
non–STEMI patients. Participation in these registries is
voluntary and subject to approval by the institutional
review board of each institution. These data are
collected as part of quality improvement programs in
participating hospitalswith deﬁneddata quality report
speciﬁcations for data capture and transmission, as
well as an auditing program; therefore, a waiver of
informed consent was granted to all sites.
As described previously, the ACTION Registry–
GWTG and CathPCI Registry datasets were linked to
create a novel single ﬁle of patients with records
in both registries (18). Data on patients’ demographic
characteristics, medical history, treatment modality,
medications (at home, in-hospital, and at discharge)
were obtained from the ACTION Registry–GWTG.
Angiographic and procedural data and periprocedural
outcomes were obtained from the CathPCI Registry.
This merge resulted in a total of 24,214 matched
STEMI patients with a record in both the ACTION
Registry–GWTG and CathPCI Registry. We excluded
patients who had cardiogenic shock or cardiac arrest
on presentation (n ¼ 2,103) as reperfusion decision
making for these patients is likely different than
that for other more hemodynamically stable STEMIh grants to the Duke Clinical Research Institute from
xoSmithKline, and Regeneron Pharmaceuticals; and
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1956patients. We then excluded 6,109 patients who un-
derwent interhospital transfer for reperfusion
because this introduces a delay to reperfusion. Due to
U.S. privacy laws, we excluded 220 patients who were
transferred out from the National Cardiovascular
Data Registry hospital as post-transfer outcomes
could not be ascertained. Finally, we excluded 19
patients who were missing information on previous
CABG or previous PCI status. For patients with mul-
tiple MI admissions in National Cardiovascular Data
Registry, we used the ﬁrst MI admission to avoid
double counting the patient. Our ﬁnal study popula-
tion included 15,628 STEMI patients treated at 297
U.S. hospitals between June 13, 2009 and September
28, 2011.
DATA COLLECTION AND DEFINITIONS. All patient
clinical and angiographic characteristics, procedural
details, length of hospital stay, and in-hospital out-
comes are collected at each participating institution
using standardized data elements and deﬁnitions and
exported in a standard format to the American College
of Cardiology (www.ncdr.com). The CathPCI Registry
captures detailed angiographic information including
lesion location, pre-procedural stenosis, and pre-
procedural Thrombolysis In Myocardial Infarction
ﬂow grade. If no culprit lesion was designated for the
STEMI patient, then the ﬁrst lesion treated was
considered the infarct-related artery. The CathPCI
Registry also denotes whether the culprit lesion was
located in a bypass graft or native coronary artery and
whether in a previously treated versus de novo coro-
nary location. The outcomes of interest in this study
included door-to-balloon time, in-hospital mortality,
in-hospital major adverse cardiac or cerebrovascular
events (MACCE), deﬁned as the composite of death,
nonfatal MI, or stroke, and in-hospital major bleeding,
deﬁned as absolute hemoglobin drop (baseline to
nadir) $4 g/dl, intracranial hemorrhage, retroperito-
neal hemorrhage, use of red blood cell transfusion in
patients with a baseline hemoglobin $9.0 g/dl, and
use of red blood cell transfusion among patients with
a baseline hemoglobin <9.0 g/dl and a witnessed
bleeding event (19).
STATISTICAL ANALYSIS. We divided the study pop-
ulation into STEMI patients with a history of PCI, a
history of CABG, and a history of no previous revas-
cularization. Patients with previous CABG were
further analyzed according to whether the PCI treated
a graft or a native vessel. Similarly, patients with a
history of PCI were analyzed on the basis of whether
the lesion was in a previously stented location or
in a de novo location. Categorical variables were
compared between groups using the Pearson chi-square test. Continuous variables are presented as
medians and compared between groups using the
Kruskal-Wallis test.
Multivariable logistic regression models, which
used generalized estimating equations to account for
correlation within sites, were used to examine the
association between each group and the outcomes
of interest. Covariates used in each model were
selected on the basis of a combination of previous risk
models, clinical judgment, and signiﬁcant differences
observed in univariable comparisons between groups
and included age, sex, race, insurance status, weight,
presenting heart rate, presenting systolic blood
pressure, hypertension, diabetes mellitus, peripheral
arterial disease, smoking status, dyslipidemia, dial-
ysis, chronic lung disease, atrial ﬁbrillation/ﬂutter,
previous MI, previous heart failure, previous stroke,
home use of a P2Y12 receptor inhibitor, baseline he-
moglobin, baseline creatinine, baseline troponin,
culprit artery, pre-procedural Thrombolysis In
Myocardial Infarction ﬂow grade, previously stented
lesion, lesion in a graft, lesion complexity, lesion
length, the presence of thrombus, and a bifurcation
lesion. All comparisons used patients without previ-
ous revascularization as the reference group. For a
lesion in a graft, comparisons are made with a lesion
in a native vessel.
RESULTS
Between June 2009 and September 2011, a total of
15,628 patients underwent primary PCI at 297 hospi-
tals in the United States, of these, 969 (6%) had a
history of CABG, 3,010 (19%) had a previous PCI, and
the majority (n ¼ 11,649 [75%]) had no history of
coronary artery revascularization. As shown in
Table 1, there were signiﬁcant clinical differences
among the groups. STEMI patients with a history of
CABG were signiﬁcantly older than patients with a
previous PCI or those without previous revasculari-
zation (66 years vs. 60 years and 59 years, respec-
tively; p < 0.001). Additionally, previous CABG
patients had higher rates of hypertension, dyslipide-
mia, diabetes, peripheral vascular disease, chronic
lung disease, cerebrovascular disease, and end-stage
renal disease on dialysis compared with patients
who had previous PCI or no previous revasculariza-
tion (p < 0.001 for all). Regarding angiographic and
procedural characteristics, there were also signiﬁcant
differences among the 3 groups, particularly between
patients with a history of CABG and those patients
with either a history of PCI or without previous PCI,
as shown in Table 2 and Figure 1. In patients with
previous PCI or without a history of coronary
TABLE 2 Angiographic and Procedural Characteristics
Previous CABG
(n ¼ 969)
Previous PCI
(n ¼ 3,010)
No Previous
Revascularization
(n ¼ 11,649) p Value
Culprit artery <0.0001
Left main 13 (1.4) 5 (0.2) 27 (0.2)
Left anterior descending 139 (14.5) 1,195 (39.8) 4,555 (39.2)
Left circumﬂex 271 (28.3) 403 (13.4) 1,597 (13.8)
Right coronary 536 (55.9) 1,398 (46.6) 5,437 (46.8)
Thrombus present 572 (59.2) 1,820 (60.5) 6,330 (54.4) <0.0001
Previously stented lesion 151 (15.6) 1,274 (42.4) N/A <0.0001
Multivessel PCI 56 (5.8) 136 (4.5) 513 (4.4) 0.12
Drug-eluting stent 480 (49.5) 1,477 (49.1) 6,406 (55.0) <0.0001
Bifurcation lesion 61 (6.3) 387 (12.9) 1,347 (11.6) <0.0001
Lesion complexity: high/C 703 (72.9) 2,051 (68.3) 7,879 (67.7) 0.004
Ejection fraction
>50% 407 (42) 1,372 (45.6) 6,430 (55.2) <0.0001
<25% 62 (6.4) 121 (4.0) 268 (2.3) <0.0001
Values are n (%).
N/A = not applicable; other abbreviations as in Table 1.
TABLE 1 Demographics and Baseline Clinical Characteristics
Previous CABG
(n ¼ 969)
Previous PCI
(n ¼ 3,010)
No Previous
Revascularization
(n ¼ 11,649) p Value
Demographic characteristics
Age, yrs 66 60 59 <0.001
Male 764 (78.8) 2,318 (77.0) 8,218 (70.6) <0.001
Race <0.001
White 871 (90.0) 2,570 (85.6) 9,815 (84.5)
Black 50 (5.2) 290 (9.7) 1,054 (9.1)
Hispanic 31 (3.2) 100 (3.3) 515 (4.4)
Asian 10 (1.0) 30 (1.0) 186 (1.6)
Others 6 (0.6) 11 (0.4) 41 (0.4)
Medical history
Current smoker 318 (32.8) 1,453 (48.3) 5,330 (45.8) <0.0001
Hypertension 853 (88.0) 2,481 (82.5) 6,739 (57.9) <0.0001
Dyslipidemia 845 (87.2) 2,509 (83.4) 5,465 (46.9) <0.001
Diabetes mellitus 358 (37.0) 854 (28.4) 2,330 (20.0) <0.001
Peripheral vascular disease 170 (17.6) 243 (8.1) 431 (3.7) <0.001
Chronic lung disease 141 (14.6) 369 (12.3) 879 (7.6) <0.001
Congestive heart failure 124 (12.8) 245 (8.2) 233 (2.0) <0.001
Previous myocardial infarction 561 (58.0) 1,986 (66.0) 460 (4.0) <0.0001
Previous cerebrovascular event 77 (8.0) 180 (6.0) 424 (3.6) <0.0001
Chronic dialysis 15 (1.6) 33 (1.1) 71 (0.6) 0.0003
Values are n (%).
CABG ¼ coronary artery bypass graft surgery; PCI ¼ percutaneous coronary intervention.
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1957revascularization, intervention for the right coronary
artery was more frequent, whereas for patients with
previous CABG, multivessel PCI, intervention for the
right coronary artery, or a bypass graft was more
frequently performed. PCI for a previously stented
lesion was performed in 42.4% of previous PCI pa-
tients; PCI for a graft lesion was performed in 54.4%
of previous CABG patients (Figure 1). The use of drug
eluting stents was approximately 50% in this acute
STEMI population; however this percentage was
slightly higher (54%) in patients without previous
revascularization (Table 2). In addition, a higher per-
centage of previous CABG patients had reduced left
ventricular ejection fraction compared with the other
2 groups (Table 2).
REPERFUSION TIME AND PROCEDURAL SUCCESS.
A lower percentage of patients with a history of
CABG achieved a door-to-balloon time of #90 min
compared with patients with a history of PCI and
patients with no previous revascularization (76.4%
vs. 88.5% vs. 88.0%) (Figure 2A). A door-to-balloon
time of #90 min was achieved in 90.1% of patients
with a history of PCI with the culprit lesion in a pre-
vious stent location and in 87.3% if the lesion was in a
nonstented region (Figure 2B). Conversely, only
75.9% of patients with a history of CABG achieved an
appropriate door-to-balloon time of #90 min when
the culprit lesion was located in a CABG graft and in
77% in patients with a previous CABG when the lesion
was located in a native vessel, which was signiﬁcantly
less than in patients without previous revasculariza-
tion (Figure 2A). Overall procedural success was ach-
ieved in 93.8% of the total study population.
However, in patients with a history of CABG, proce-
dural success was achieved in only 88.3% of patients
compared with 93.4% of patients with a history of PCI
and 94.4% of patients without a history of revascu-
larization (p < 0.0001).
IN-HOSPITAL OUTCOMES FOR PATIENTS WITH
PREVIOUS CABG. As seen in Table 3 and Figure 3,
patients with a history of CABG undergoing primary
PCI had signiﬁcantly higher unadjusted in-hospital
mortality and MACCE risk than did patients without
previous revascularization (odds ratio [OR]: 1.73, 95%
conﬁdence interval [CI]: 1.15 to 2.60, p ¼ 0.009 and
OR: 1.68, 95% CI: 1.23 to 2.31, p ¼ 0.001, respectively).
However, after multivariable adjustment, this differ-
ence was no longer present (OR: 1.03, 95% CI: 0.64 to
1.68, p ¼ 0.89 and OR: 1.07, 95% CI: 0.77 to 1.49,
p ¼ 0.69, respectively) (Table 3). There was a trend for
an increased mortality risk in the unadjusted and the
adjusted model if the treated lesion was in a bypass
graft versus a previous coronary artery bypass graftwith the lesion in a native vessel (OR: 2.18, 95% CI:
0.95 to 4.98, p ¼ 0.07 and OR: 2.20, 95% CI: 0.93 to
5.17, p ¼ 0.07), but not if the lesion was in a native
coronary artery compared with no previous revascu-
larization (OR: 1.13, 95% CI: 0.55 to 2.33 and OR: 0.67,
95% CI: 0.31 to 1.48, p ¼ 0.32, respectively). Unad-
justed and adjusted MACCE risk was similar when
FIGURE 1 Target Vessel in Prior CABG and PCI Patients
(A) Percentage of patients with a lesion in a graft, internal mammary graft, or native vessel. (B) Target vessel in patients with a history of CABG.
(C) Target vessel in patients with a history of PCI. (D) Target vessel in patients with no history of revascularization. LAD ¼ left anterior
descending artery; LCx ¼ left circumﬂex artery; LMCA ¼ left main coronary artery; PCI ¼ percutaneous coronary intervention; RCA ¼ right
coronary artery.
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1958comparing primary PCI in a lesion located in a bypass
graft versus a native coronary artery and between
primary PCI in a native vessel versus in patients with
no previous revascularization (Table 3). Likewise,
major bleeding risk was similar in the unadjusted andFIGURE 2 Percentage of Patients With Reperfusion Time <90 Minu
(A) Percentage of patients with a history of CABG for whom a door-to-b
history of PCI for whom a door-to-balloon time <90 min was achieved.adjusted models for all patients with a history of
CABG compared with patients with no previous
revascularization (OR: 1.13, 95% CI: 0.92 to 1.38,
p ¼ 0.26 and OR: 0.91, 95% CI: 0.68 to 1.20, p ¼ 0.49),
regardless of lesion location. However, it is importanttes
alloon time <90 min was achieved. (B) Percentage of patients with a
Abbreviations as in Figure 2.
TABLE 3 In-Hospital Outcomes in Patients With Previous CABG
Outcome*
Previous CABG
No Previous
Revascularization
All CABG
Patients Lesion in Graft
Lesion in Native
Vessel
Mortality
Event rate 3.3 (32/969) 4.3 (23/529) 2.0 (9/440) 1.8 (211/11,649)
Unadjusted model
OR (95% CI) 1.73 (1.15–2.60) 2.18 (0.95–4.98) 1.13 (0.55–2.33) Reference
p value 0.0089 0.065 0.74
Adjusted model
OR (95% CI) 1.03 (0.64–1.68) 2.20 (0.93–5.17) 0.67 (0.31–1.48) Reference
p value 0.89 0.072 0.32
MACCE
Event rate 5.1 (49/963) 5.9 (31/526) 4.1 (18/437) 3.0 (354/11,625)
Unadjusted model
OR (95% CI) 1.68 (1.23–2.31) 1.44 (0.78–2.67) 1.38 (0.83–2.29)
p value 0.0013 0.24 0.21
Adjusted model
OR (95% CI) 1.07 (0.77–1.49) 1.35 (0.70–2.58) 0.91 (0.55–1.51)
p value 0.69 0.37 0.71
Major bleeding
Event rate 9.6 (92/954) 9.8 (51/519) 9.4 (41/435) 8.5 (980/11,519)
Unadjusted model
OR (95% CI) 1.13 (0.92–1.38) 1.03 (0.70–1.52) 1.11 (0.82–1.49)
p value 0.26 0.88 0.50
Adjusted model
OR (95% CI) 0.91 (0.68–1.20) 1.11 (0.73–1.70) 0.86 (0.59–1.24)
p value 0.49 0.62 0.41
Values are % (n/N) unless otherwise speciﬁed. *Unadjusted and adjusted models for all CABG patients and a
lesion in a native vessel are performed using patients without previous revascularization as the reference group.
For a lesion in a graft, comparisons are made with a lesion in a native vessel.
CI ¼ conﬁdence interval; MACCE ¼ major adverse cardiac or cerebrovascular event; OR ¼ odds ratio; other
abbreviations as in Table 1.
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1959to note that this was an analysis of a smaller number
of patients.
IN-HOSPITAL OUTCOMES FOR PATIENTS WITH A
PREVIOUS PCI. When comparing patients with a
history of PCI with patients with no previous revas-
cularization, risk was similar in the unadjusted and
adjusted model for mortality (OR: 1.23, 95% CI: 0.96
to 1.58, p ¼ 0.10 and OR: 1.12, 95% CI: 0.76 to 1.63,
p ¼ 0.57, respectively), as were MACCE risk (OR: 1.10,
95% CI: 0.89 to 1.37, p ¼ 0.38 and OR: 0.90, 95% CI:
0.68 to 1.18, p ¼ 0.44, respectively) (Table 4). Mor-
tality risk was similar in the unadjusted and adjusted
models when patients underwent PCI of a previously
stented lesion compared with patients who had a
history of PCI, but the lesion was located in a
different lesion (OR: 0.86, 95% CI: 0.55 to 1.35,
p ¼ 0.51 and OR: 0.77, 95% CI: 0.46 to 1.29, p ¼ 0.32).
However, there was a trend for a lower MACCE risk
for patients undergoing primary PCI of a previously
stented lesion, for both the unadjusted and adjusted
models (OR: 0.76, 95% CI: 0.53 to 1.09, p ¼ 0.13 and
OR: 0.67, 95% CI: 0.45 to 1.00, p ¼ 0.05, respectively).
Patients with a history of PCI who had the infarct-
related lesion in a new location (de novo lesion) had
a trend toward a higher mortality and MACCE risk
compared with patients without previous revascu-
larization in the unadjusted model (OR: 1.31, 95% CI:
0.98 to 1.75, p ¼ 0.07 and OR: 1.24, 95% CI: 0.97 to
1.58, p ¼ 0.09) but not in the adjusted model (OR:
1.25, 95% CI: 0.82 to 1.91, p ¼ 0.30 and OR: 1.06, 95%
CI: 0.78 to 1.44, p ¼ 0.70) (Table 4). Major bleeding
risk was similar in the unadjusted and adjusted
models for all patients with a history of PCI compared
with patients with no previous revascularization in
the unadjusted and adjusted models (OR: 0.88, 95%
CI: 0.76 to 1.03, p ¼ 0.11 and OR: 0.87, 95% CI: 0.71 to
1.05, p ¼ 0.14), respectively. Bleeding rates were
similar in patients with a lesion located in a previ-
ously stented lesion compared with patients who had
a de novo lesion in the unadjusted and adjusted
models (OR: 1.05, 95% CI: 0.81 to 1.36, p ¼ 0.70 and
OR: 0.98, 95 CI: 0.75 to 1.29, p ¼ 0.90) and in patients
undergoing primary PCI in a de novo lesion compared
with patients without previous revascularization in
the adjusted and unadjusted models (OR: 0.86, 95%
CI: 0.71 to 1.05, p ¼ 0.14 and OR: 0.87, 95% CI: 0.70 to
1.09, p ¼ 0.23) (Table 4).
DISCUSSION
The major ﬁndings of our study in a contemporary,
nationally representative database of 15,628 patients
undergoing primary PCI for STEMI in the United
States are the following; 1) patients with a history ofCABG had longer delays to reperfusion than those
without previous revascularization; 2) unadjusted in-
hospital mortality and MACCE risk was signiﬁcantly
higher in patients with a history of CABG. However,
after risk adjustment, there were no signiﬁcant
differences in in-hospital outcomes compared with
patients without previous revascularization; 3) there
was a trend toward higher in-hospital mortality risk in
patients undergoing primary PCI in a lesion located in a
CABG graft; 4) a higher percentage of patients with a
history of PCI undergoing primary PCI in a previously
stented lesion achieved a door-to balloon time of #90
min; and 5) There was a trend toward lower in-hospital
mortality and MACCE risk in patients undergoing pri-
mary PCI in a previously stented lesion.
In this study, we sought to assess the outcomes
of patients with a history of revascularization,
either by CABG or PCI, and compare them with pa-
tients with no history of a revascularization proce-
dure. No randomized trial or retrospective study
has directly compared the outcomes of these 3
groups. As expected, these 3 groups of patients were
TABLE 4 In-Hospital Outcomes in Patients With Previous PCI
Outcome*
Previous PCI
No Previous
RevascularizationAll PCI Patients
Previously
Stented Lesion
Not Previously
Stented Lesion
Mortality
Event rate 2.2 (67/3,010) 2.0 (26/1,274) 2.4 (41/1,736) 1.8 (211/11,649)
Unadjusted model
OR (95% CI) 1.23 (0.96–1.58) 0.86 (0.55–1.35) 1.31 (0.98–1.75)
p value 0.10 0.51 0.065
Adjusted model
OR (95% CI) 1.12 (0.76–1.63) 0.77 (0.46–1.29) 1.25 (0.82–1.91)
p value 0.57 0.32 0.30
MACCE
Event rate 3.4 (101/3,005) 2.9 (37/1,271) 3.7 (64/1,734) 3.0 (354/11,625)
Unadjusted model
OR (95% CI) 1.10 (0.89–1.37) 0.76 (0.53–1.09) 1.24 (0.97–1.58)
p value 0.38 0.13 0.088
Adjusted model
OR (95% CI) 0.90 (0.68–1.18) 0.67 (0.45–1.00) 1.06 (0.78–1.44)
p value 0.44 0.051 0.70
Major bleeding
Event rate 7.6 (225/2,975) 7.8 (98/1,258) 7.4 (127/1,717) 8.5 (980/11,519)
Unadjusted model
OR (95% CI) 0.88 (0.76–1.03) 1.05 (0.81–1.36) 0.86 (0.71–1.05)
p value 0.11 0.70 0.14
Adjusted model
OR (95% CI) 0.87 (0.71–1.05) 0.98 (0.75–1.29) 0.87 (0.70–1.09)
p value 0.14 0.90 0.23
Values are % (n/N) unless otherwise speciﬁed. *Unadjusted and adjusted models for all coronary artery bypass
graft surgery patients and a lesion in a native vessel are performed using patients without previous revas-
cularization as the reference group. For a lesion in a graft, comparisons are made with a lesion in a native
vessel.
Abbreviations as in Tables 2 and 3.
FIGURE 3 In-Hospital Crude Mortality, MACCE, and Major Bleeding Rates
MACCE ¼ major adverse cardiovascular or cerebrovascular event(s); other abbreviations as
in Figure 1.
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1960signiﬁcantly different regarding baseline clinical,
angiographic and procedural characteristics and
therefore the need for adjustment for confounding
variables. The present study shows that 24% of pa-
tients with a history of CABG did not achieve the 90-
min door-to-balloon time standard set by the Amer-
ican College of Cardiology, the American Heart As-
sociation, and the Society for Cardiac Angiography
and Interventions guidelines for the treatment of
STEMI, particularly when the infarct-related artery
was a bypass graft. Furthermore, in 12% of these pa-
tients, the operator was unable to successfully treat
the lesion compared with 7% of patients with a his-
tory of PCI and 6% of revascularization-naïve pa-
tients. These reperfusion rates are very similar to the
rates reported by O’Keefe et al. (20) in 1993, Stone
et al. (15) in 2000, and Welsh et al. (4) in 2010 (4,15),
and it would seem that success rates in the acute MI
setting have not improved in the past 20 years despite
technological and pharmacological advances in
interventional cardiology. Hence, it is possible that
patients with a history of CABG did not achieve fast
and successful reperfusion due to the complexity of
the infarct-related artery and/or lesion and the lo-
gistics associated with this patient population (1,20–
22). Although in our study, the unadjusted in-
hospital mortality and MACCE rates were signiﬁ-
cantly higher for patients with previous CABG, after
multivariable adjustment, the risk of these adverse
events was similar to that in STEMI patients without
previous revascularization. However, the lack of
long-term follow-up precludes us from observing
longer term outcomes associated with these reperfu-
sion challenges.
Although the efﬁcacy of timely reperfusion in
STEMI patients has been well established in pre-
vious clinical trials, the data for patients with a his-
tory of CABG are less conclusive; whereas some
studies have shown that these patients have worse
angiographic results and increased mortality rates,
others have shown no difference in outcomes after
multivariable logistic regression analysis correcting
for baseline differences (4,14). In our study, we
observed a strong trend for increased in-hospital
mortality risk when the infarct-related lesion
was in a bypass graft and a similar mortality risk
when the infarct-related lesion was located in a
native vessel versus in a patient without previous
revascularization.
Among all patients with a history of PCI presenting
with STEMI, the door-to-balloon time was similar
compared with patients who had no history of
revascularization. However, the door-to-balloon time
was signiﬁcantly shorter when the infarct-related
PERSPECTIVES
WHAT IS KNOWN? Prompt revascularization of the infarct-
related artery is currently the default strategy in patients pre-
senting with STEMI. Also, it should be performed in a timely
manner, with a recommended door-to-balloon time of #90 min
for patients undergoing PCI.
WHAT IS NEW? Patients with a history of CABG have more
complex anatomy and more comorbidities and therefore have a
more prolonged door-to-balloon time compared with patients
with a history of PCI or those who never had a previous revas-
cularization procedure. However, after risk adjustment for mul-
tiple clinical, angiographic, and procedural differences between
the groups, patients with previous CABG had in-hospital out-
comes similar to those of patients with a previous PCI and pa-
tients who never had a previous revascularization procedure. No
signiﬁcant differences in reperfusion timeliness or in-hospital
outcomes were seen in patients with a history of PCI compared
with patients without previous revascularization.
WHAT IS NEXT? These ﬁndings should be veriﬁed in other
large databases. Every effort should be made to improve reper-
fusion timeliness in patients with a history of CABG.
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1961lesion was in a previously stented lesion, and there
was a trend toward lower in-hospital MACCE risk in
these patients in the adjusted model (p ¼ 0.05).
Overall procedural success, in-hospital mortality,
and MACCE and major bleeding risk were similar in
the adjusted and unadjusted models for all patients
with a history of PCI compared with patients without
previous revascularization. A recent publication by
Chin et al. (16) that examined all acute MI patients
(STEMI and non-STEMI) who underwent PCI in the
CathPCI Registry showed that patients with a history
of PCI had lower mortality rates compared with
patients undergoing a ﬁrst PCI, despite a higher risk
proﬁle. The results of our study focusing on
STEMI patients only showed similar in-hospital
mortality, MACCE, and bleeding rates in patients
with a previous PCI and patients without previous
revascularization.
STUDY LIMITATIONS. The major limitation of this
study is the observational nature of the analysis, and,
although the data are collected at all sites using
standardized deﬁnitions, the events are not inde-
pendently adjudicated. Despite the large number of
patients in all 3 groups, there were substantial
differences among the groups, and unmeasured
confounders are not accounted for despite rigorous
multivariable analysis. The lack of long-term follow-
up constitutes an important limitation because out-
comes may differ signiﬁcantly among the 3 groups as
time elapses.
CONCLUSIONS
Analysis of this large and contemporary cohort of
patients showed that patients with a history of CABG
undergoing primary PCI in the setting of acute STEMI
are older, have multiple comorbidities, and are
less likely to achieve successful reperfusion and
a door-to-balloon time of #90 min compared
with patients without previous revascularization.
Conversely, patients with a history of PCI achieved
similar reperfusion rates and door-to-balloon time
of #90 min compared with patients without previousrevascularization and even shorter door-to-balloon
times when the infarct-related lesion was located in
a previously stented lesion. After risk adjustment for
multiple clinical, angiographic, and procedural dif-
ferences between groups, there was no signiﬁcant
difference in in-hospital mortality, MACCE, and major
bleeding among the 3 groups. Mechanisms to opti-
mize door-to-balloon time and improve success of
reperfusion in patients with previous CABG should be
a priority for future research.
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